Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective

Yuben Moodley, T.J. Corte, L. Richeldi, T.E. King

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

© 2015 Asian Pacific Society of Respirology. Idiopathic pulmonary fibrosis (IPF) is an incurable condition that is characterized by progressive pulmonary fibrosis, architectural distortion of the lung and loss of gas exchange units. Until recently, there was no effective treatment for this condition. However, there were two landmark trials published earlier this year, which have changed the management of this condition. Pirfenidone (Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis trial) and nintedanib (Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis-1 and -2 trials) have both demonstrated positive outcomes in patients with IPF. In this perspective, we critically discuss the role of these agents in IPF and in the broader pulmonary fibrosis population.
Original languageEnglish
Pages (from-to)389-394
JournalRespirology
Volume20
Issue number3
DOIs
Publication statusPublished - 2015

Fingerprint

Idiopathic Pulmonary Fibrosis
Pulmonary Fibrosis
Therapeutics
Safety
Gases
Lung
Population

Cite this

@article{1030fc118edf4b40af29aecb6e740834,
title = "Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective",
abstract = "{\circledC} 2015 Asian Pacific Society of Respirology. Idiopathic pulmonary fibrosis (IPF) is an incurable condition that is characterized by progressive pulmonary fibrosis, architectural distortion of the lung and loss of gas exchange units. Until recently, there was no effective treatment for this condition. However, there were two landmark trials published earlier this year, which have changed the management of this condition. Pirfenidone (Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis trial) and nintedanib (Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis-1 and -2 trials) have both demonstrated positive outcomes in patients with IPF. In this perspective, we critically discuss the role of these agents in IPF and in the broader pulmonary fibrosis population.",
author = "Yuben Moodley and T.J. Corte and L. Richeldi and T.E. King",
year = "2015",
doi = "10.1111/resp.12484",
language = "English",
volume = "20",
pages = "389--394",
journal = "Asian Pacific Journal of Respirology",
issn = "1323-7799",
publisher = "John Wiley & Sons",
number = "3",

}

Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective. / Moodley, Yuben; Corte, T.J.; Richeldi, L.; King, T.E.

In: Respirology, Vol. 20, No. 3, 2015, p. 389-394.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective

AU - Moodley, Yuben

AU - Corte, T.J.

AU - Richeldi, L.

AU - King, T.E.

PY - 2015

Y1 - 2015

N2 - © 2015 Asian Pacific Society of Respirology. Idiopathic pulmonary fibrosis (IPF) is an incurable condition that is characterized by progressive pulmonary fibrosis, architectural distortion of the lung and loss of gas exchange units. Until recently, there was no effective treatment for this condition. However, there were two landmark trials published earlier this year, which have changed the management of this condition. Pirfenidone (Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis trial) and nintedanib (Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis-1 and -2 trials) have both demonstrated positive outcomes in patients with IPF. In this perspective, we critically discuss the role of these agents in IPF and in the broader pulmonary fibrosis population.

AB - © 2015 Asian Pacific Society of Respirology. Idiopathic pulmonary fibrosis (IPF) is an incurable condition that is characterized by progressive pulmonary fibrosis, architectural distortion of the lung and loss of gas exchange units. Until recently, there was no effective treatment for this condition. However, there were two landmark trials published earlier this year, which have changed the management of this condition. Pirfenidone (Assessment of Pirfenidone to Confirm Efficacy and Safety in Idiopathic Pulmonary Fibrosis trial) and nintedanib (Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis-1 and -2 trials) have both demonstrated positive outcomes in patients with IPF. In this perspective, we critically discuss the role of these agents in IPF and in the broader pulmonary fibrosis population.

U2 - 10.1111/resp.12484

DO - 10.1111/resp.12484

M3 - Article

VL - 20

SP - 389

EP - 394

JO - Asian Pacific Journal of Respirology

JF - Asian Pacific Journal of Respirology

SN - 1323-7799

IS - 3

ER -